Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV NEPA vs Oral NEPA for CINV in Breast Cancer
NCT03403712Phase 3Completed
- Sponsor
- Helsinn
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of fosnetupitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Helsinn. Started Mar 2018; status: completed.
02
Drugs
fosnetupitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03403712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403712.